Food Triggers for Psoriasis: What to Eat and What to Avoid

We include products we think are useful for our readers. If you buy through links on this page, we may earn a small commission. Heres our process.

When you have psoriasis, reducing triggers is an important part of managing your condition and avoiding flare-ups. Psoriasis flare-ups can be caused by a variety of triggers. These triggers may include bad weather, excess stress, and certain foods.

Lets take a look at the foods that are most likely to trigger a psoriasis flare-up. There are some foods that are helpful to incorporate and certain diets to consider when creating a treatment plan for your psoriasis.

The foods listed below have been reported to trigger flare-ups, but they may not affect all those affected by psoriasis.

With psoriasis, its important to avoid foods that can trigger inflammation. Inflammation and the immune system response can lead to a flare-up.

Both red meat and dairy, especially eggs, contain a polyunsaturated fatty acid called arachidonic acid. Past research has shown that by-products of arachidonic acid may play a role in creating psoriatic lesions.

Foods to avoid include:

Celiac disease is a health condition characterized by an autoimmune response to the protein gluten. People with psoriasis have been found to have increased markers for gluten sensitivity. If you have psoriasis and a gluten sensitivity, its important to cut out gluten-containing foods.

Foods to avoid include:

Eating too many processed, high-calorie foods can lead to obesity, metabolic syndrome, and a variety of chronic health conditions. Certain conditions such as these cause chronic inflammation in the body, which may be linked to psoriasis flare-ups.

Foods to avoid include:

One of the most commonly reported triggers for psoriasis flare-ups is the consumption of nightshades. Nightshade plants contain solanine, which has been known to affect digestion in humans and may be a cause of inflammation.

Foods to avoid include:

Autoimmune flare-ups are linked to the health of the immune system. Alcohol is believed to be a psoriasis trigger due to its disruptive effects on the various pathways of the immune system. If you have psoriasis, it may be best to drink alcohol very sparingly.

With psoriasis, a diet high in anti-inflammatory foods can help to reduce the severity of a flare-up.

Almost all anti-inflammatory diets include fruits and vegetables. Fruits and vegetables are high in antioxidants, which are compounds that decrease oxidative stress and inflammation. A diet high in fruits and vegetables is recommended for inflammatory conditions such as psoriasis.

Foods to eat include:

A diet high in fatty fish can provide the body with anti-inflammatory omega-3s. The intake of omega-3s has been linked to a decrease of inflammatory substances and overall inflammation.

Fish to eat include:

It should be noted that there is still more research that needs to be done on the link between omega-3s and psoriasis.

Like fatty fish, certain vegetable oils also contain anti-inflammatory fatty acids. Its important to focus on oils that have a higher ratio of omega-3 to omega-6 fatty acids.

Oils to eat include:

A 2013 review of research literature showed that nutritional supplements may help reduce inflammation in psoriasis. Fish oil, vitamin D, vitamin B-12, and selenium have all been researched for psoriasis.

Benefits of supplementation with these nutrients may include a decrease in the frequency and severity of flare-ups.

Not all diets are good for psoriasis. Here are some options you may want to consider when choosing the best diet for your condition.

Dr. Pagano was well known within the health and wellness community for his approach to healing psoriasis through diet. In his book, Healing Psoriasis: The Natural Alternative, he describes how a healthy diet and lifestyle can improve psoriasis naturally.

Dr. Paganos dietary approach includes:

A 2017 survey of more than 1,200 people with psoriasis indicated that the Pagano diet is one of the most successful diets for improving psoriasis outcomes.

In people who have both psoriasis and gluten sensitivities, a gluten-free diet may provide some improvement. One small 2018 study found that even people with mild gluten sensitivities can benefit from following a gluten-free diet.

Of the 13 participants who were placed on a gluten-free diet, all observed an improvement in their psoriatic lesions. The biggest benefit was observed for those participants with the strongest sensitivity.

A vegan diet may also benefit people with psoriasis. This diet is naturally low in inflammatory foods such as red meat and dairy. Its high in anti-inflammatory foods such as fruits, vegetables, and healthy oils.

Like the Dr. Pagano diet, the vegan diet also showed favorable results in study participants with psoriasis.

Speak with your doctor about following a vegan diet, as you need to be careful to get all the nutrients you need.

The Mediterranean Diet is well known for its numerous health benefits, including a reduced risk of certain chronic diseases. This diet focuses on foods that are high in antioxidants and healthy fats. It limits foods that are often considered to be pro-inflammatory.

In a 2015 study, researchers found that people with psoriasis are less likely to be consuming a Mediterranean-type diet than their healthy counterparts. They also found that those who did adhere to elements of the Mediterranean diet had a lower disease severity.

The paleo diet places an emphasis on eating whole foods and avoiding processed foods. Since many whole foods contain anti-inflammatory compounds, this diet may prove to be beneficial for people with psoriasis.

Unlike Dr. Paganos diet, it involves eating plenty of meat and fish. However, the 2017 research suggests that the paleo diet is the third most effective diet in people with psoriasis.

The autoimmune protocol diet (AIP) focuses on eliminating foods that might cause inflammation. This diet is incredibly restrictive and primarily includes vegetables and meat, with certain oils and herbs mixed in.

It might not be appropriate for people with psoriasis, as too much meat is considered a trigger for flare-ups. In addition, its not intended to be a long-term dietary intervention.

This popular low-carb diet has many touted health benefits, such as weight loss and improved nutrient markers. Its true that reducing carbohydrates can help reduce processed food intake.

However, reducing carbohydrates also means reducing many anti-inflammatory fruits and vegetables. It also necessitates increasing protein from meat. Because certain keto foods can be triggers in people with psoriasis, this diet may not be recommended.

Many autoimmune conditions such as psoriasis can benefit from dietary changes. If you have psoriasis, you may find it beneficial to include plenty of anti-inflammatory foods, such as fruits, vegetables, and healthy oils.

You may also want to avoid pro-inflammatory foods, such as meat, dairy, and processed foods. These dietary changes may help to reduce the frequency and severity of your flare-ups.

Its always best to reach out to a physician or nutritionist for more information on how your diet can help control your condition.

See the original post here:

Food Triggers for Psoriasis: What to Eat and What to Avoid

Psoriatic Arthritis: Causes, Symptoms, and Treatments – Self

Overview

Psoriatic arthritis is a form of arthritis that affects some people who have psoriasisa condition that features red patches of skin topped with silvery scales. Most people develop psoriasis first and are later diagnosed with psoriatic arthritis, but the joint problems can sometimes begin before skin lesions appear.

Joint pain, stiffness, and swelling are the main symptoms of psoriatic arthritis. They can affect any part of your body, including your fingertips and spine, and can range from relatively mild to severe. In both psoriasis and psoriatic arthritis, disease flares may alternate with periods of remission.

No cure for psoriatic arthritis exists, so the focus is on controlling symptoms and preventing damage to your joints. Without treatment, psoriatic arthritis may be disabling.

Symptoms

Both psoriatic arthritis and psoriasis are chronic diseases that get worse over time, but you may have periods when your symptoms improve or go into remission alternating with times when symptoms become worse.

Psoriatic arthritis can affect joints on just one side or on both sides of your body. The signs and symptoms of psoriatic arthritis often resemble those of rheumatoid arthritis. Both diseases cause joints to become painful, swollen, and warm to the touch.

However, psoriatic arthritis is more likely to also cause:

When to see a doctor

If you have psoriasis, be sure to tell your doctor if you develop joint pain. Psoriatic arthritis can severely damage your joints if left untreated.

Causes

Psoriatic arthritis occurs when your bodys immune system begins to attack healthy cells and tissue. The abnormal immune response causes inflammation in your joints as well as overproduction of skin cells.

Its not entirely clear why the immune system turns on healthy tissue, but it seems likely that both genetic and environmental factors play a role. Many people with psoriatic arthritis have a family history of either psoriasis or psoriatic arthritis. Researchers have discovered certain genetic markers that appear to be associated with psoriatic arthritis.

Physical trauma or something in the environmentsuch as a viral or bacterial infectionmay trigger psoriatic arthritis in people with an inherited tendency.

Risk factors

Several factors can increase your risk of psoriatic arthritis, including:

Complications

A small percentage of people with psoriatic arthritis develop arthritis mutilansa severe, painful, and disabling form of the disease. Over time, arthritis mutilans destroys the small bones in your hands, especially the fingers, leading to permanent deformity and disability.

Here is the original post:

Psoriatic Arthritis: Causes, Symptoms, and Treatments - Self

Plaque Psoriasis Treatment Market Poised to Grow at a Healthy CAGR of XX% During the Forecast Period 2017 2025 Bulletin Line – Bulletin Line

Evaluation of the Global Plaque Psoriasis Treatment Market

The presented study maps the growth trajectory of the global Plaque Psoriasis Treatment market by thoroughly assessing the various factors that are expected to influence the future prospects of the Plaque Psoriasis Treatment market. According to the report published by PMR, the Plaque Psoriasis Treatment market is poised to attain a value of ~US$ XX Mn/Bn by the end of 2029 with a CAGR growth of ~XX% during the forecast period (2019-2029).

A complete evaluation of the trends, market drivers, opportunities, and challenges faced by market players operating in the Plaque Psoriasis Treatment market is provided in the report. Further, an overview and introduction of the Plaque Psoriasis Treatment market is included to ensure that the readers have a seamless experience while going through the contents of the report.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/16069

Critical insights included in the report:

Competitive Outlook

The competitive outlook assessment provides an in-depth understanding related to the business proceeding of top-tier market players in the global Plaque Psoriasis Treatment market. The product portfolio, sales strategy, marketing & promotional strategy, and sales footprint of each market player is scrutinized thoroughly in the report. Some of the leading players evaluated in the report include:

The report segments the global Plaque Psoriasis Treatment market on the basis of region, product type, and end use.

market players are also exploring the developing market. Novartis launched its Cosentyx in Japan for the treatment of psoriasis arthritis in adults who are not adequately responding to systemic therapy.

Plaque Psoriasis Treatment Market: Market Players

Company manufacturer is converting innovative research into a new therapy by constantly investing in research activities. The number of drugs approved for plaque psoriasis is constantly increasing the number of treatment options for the physician and patients. Eli Lillys interleukin inhibitor was approved by the FDA, second molecule to be approved after Novartis Cosentyx.

Some of the plaque psoriasis treatment market contributors are Allergan, Johnson and Johnson, Amgen, Abbvie, Eli Lilly, Dermira Inc., Novartis, Galectin Therapeutics, Cellceutix Corporation and Biogen Inc., Bayer.

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/16069

Regional Analysis

The market scenario in each region along with a comprehensive assessment of the micro and macro-economic factors that are forecasted to impact the market growth in these regions is included in the report.

End Use Assessment

The market study offers accurate and in-depth analysis of the various end uses of the Plaque Psoriasis Treatment along with a yearly comparison of the market share and revenue growth of each end use.

Important queries addressed in the report:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/16069

Why Opt for PMR?

Excerpt from:

Plaque Psoriasis Treatment Market Poised to Grow at a Healthy CAGR of XX% During the Forecast Period 2017 2025 Bulletin Line - Bulletin Line

Explained: What is Itolizumab, newly cleared for Covid? – The Indian Express

Written by Anuradha Mascarenhas | Pune | Updated: July 20, 2020 8:09:55 am The approval from the DCGI is based on the results from the conclusion of a randomised, controlled clinical trial at hospitals in Mumbai and New Delhi. (Express Photo/Praveen Khanna)

A repurposed drug, Itolizumab, is one of the newest treatments for Covid-19 approved in India. The Drug Controller General of India recently approved it as a novel biologic therapy for restricted emergency use. The decision has also sparked controversy because of the small size of the clinical trials, and because exemption has been granted from phase-III trials.

What is this drug?

Itolizumab is an existing drug used for psoriasis, a chronic skin disease involving unregulated growth of some skin cells that develop into red patches mostly on knees and elbows, but also on some other parts of the body. The drug, developed by Bengaluru-based Biocon, was approved in 2013. It is considered safe and effective for the treatment of psoriasis.

Why was it approved for emergency use in Covid treatment?

The SARS-CoV-2 virus has been observed to induce an overreaction of the immune system, generating a large number of cytokines that can cause severe damage to the lungs and other organs, and, in the worst scenario, multi-organ failure and even death.

The approval from the DCGI is based on the results from the conclusion of a randomised, controlled clinical trial at hospitals in Mumbai and New Delhi. The study focused on the safety and efficacy of Itolizumab in preventing cardio-renal complications in Covid-19 patients who also have acute respiratory distress. The drug has been found to reduce these complications in such patients.

Explained |Why community transmission no longer matters at this stage

Basically, the drug controls the hyper-activation of the immune system in response to SARS-CoV-2 virus and prevents morbidity and mortality related to the cytokine storm. The clinical trial showed that the drug is best administered in the pulmonary phase of the Covid-19 infection when the cytokine build up is starting and the patient is experiencing shortness of breath and exhibiting abnormal chest images. It prevents progression to the hyperinflammation phase (cytokine storm) and other complications like coagulation and organ failure, according to Dr Sandeep Athalye, Chief Medical Officer, Biocon Biologics.

The drug has been used over 80 patients in Cuba and off-label in over 150 cases. According to Dr Shashank Joshi, Dean, Indian College of Physicians, the most critical part is to know when to use the drug and it must be reserved for moderate to severe Covid cases with cytokine storm where oxygen requirements are rapidly going up. usually between the 8th day onwards of Covid infection.

What were the results of the trial?

The trial results showed a statistically significant advantage over the control group of patients, in one-month mortality rate. All the patients who were administered Itolizumab were weaned off oxygen by Day 30, and none needed ventilator support unlike the control group that did not get the drug. Some other inflammations commonly found in such patients were also suppressed, and these correlated well with clinical improvement in symptoms. Overall, the drug was found well-tolerated.

Express Explainedis now onTelegram. Clickhere to join our channel (@ieexplained)and stay updated with the latest

How large was the trial?

The trial had 20 participants given the drug along with supportive care and 10 others given only supportive care. All 20 patients on Itolizumab recovered while three of the other 10 patients died.

Public health experts and some doctors have used social media to question the sample size of the trial. When journalists raised this question at a virtual press conference, Kiran Mazumdar-Shaw, Executive Chairperson, Biocon, said Itolizumab has been approved in India and since the country is in a medical emergency, it was decided to go ahead with a clinical trial involving a cohort of 30 patients. She said the regulatory process was extremely robust and the scientific discussions on the trial was of a very high order.

The DCGI has also exempted the drug from phase III clinical trials and allowed phase IV trials (post-marketing surveillance). Itolizumab is not a new drug and was approved in India since 2013. We had done phase II and III trials, and got the approval. In the past seven years, its been used in psoriasis and we know how the mechanism works Biocon Biologics CMO Dr Athalye said. Company officials said they plan phase IV trials soon.

How much does it cost?

Each injection is presented as a 25mg/5ml solution, which costs Rs 7,950 per vial. Based on an average body weight of 60 kg, the therapy cost of a single dose comprising four vials is estimated at Rs 32,000 (MRP).

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Explained News, download Indian Express App.

Link:

Explained: What is Itolizumab, newly cleared for Covid? - The Indian Express

Psoriasis Drugs Market: Competitive Intelligence and Tracking Report 2018 2028 – 3rd Watch News

Growth Prospects of the Psoriasis Drugs Market

The comprehensive study on the Psoriasis Drugs Market provides crucial insights to the stakeholders who are vying to solidify their presence in the current and future market landscape. The various factors that are likely to shape the course of the Psoriasis Drugs Market over the next decade are thoroughly analyzed in the report.

The research report provides deep insights into the competitive outlook of the Psoriasis Drugs Market. The research report looks into growth strategies employed by key players, and how these strategies are poised to change the competitive dynamics in the Psoriasis Drugs Market over the forecast period. Further, our research reports include market share estimates and changing hierarchy in the Psoriasis Drugs Market over the forecast period. The influence of growth strategies on the changing hierarchy in the Psoriasis Drugs Market is also discussed in this report.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) at https://www.xploremr.com/connectus/sample/3119

Important doubts pertaining to the Psoriasis Drugs Market addressed in the report:

The extensive report fragments the Psoriasis Drugs market into multiple segments such as product type, regions, end uses, and industries.

The report provides an in-depth assessment of the numerous factors that are anticipated to impact the market dynamics with utmost precision and accuracy. The SWOT and Porters Five Forces Analysis provides a clear picture about the current operations of the various market players operating in the global Psoriasis Drugs Market.

Get Your Copy at a Discounted Rate!!! Limited Time Offer!!! https://www.xploremr.com/connectus/check-discount/3119

Competition Outlook

The market study provides valuable insights related to the major players involved in the Psoriasis Drugs Market. The study includes information related to the recent mergers, acquisitions, collaborations, product launches, and research & development activities.

The report covers exhaustive analysis on:

Regional analysis includes:

Get Full Report Access athttps://www.xploremr.com/cart/3119/SL

Analytical insights included in the report:

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

About Us

XploreMR, a leading market research firm, headquartered in San Jose, USA, XploreMR has, in a short span of time, served the market research needs of some of the biggest Fortune 500 companies. XploreMR also has highly personalized market research offerings for SMEs, and we pride ourselves on being uniquely positioned to have worked with colossal multinational firms and small, boutique firms. Our experience of working with such a diverse set from all over the world has given us invaluable perspectives on objectives, outlooks, goals, and eventually, the collective, symbiotic growth that stakeholders across the value chain aspire for. We keep these perspectives and aspirations in mind every time we work on a project, and this motivates us to exceed client expectations on a consistent basis.

Contact us:

XploreMR111 North Market Street, Suite 300,San Jose, CA 95113, United StatesPh.No: +16692840108E-mail id- [emailprotected]

Continue reading here:

Psoriasis Drugs Market: Competitive Intelligence and Tracking Report 2018 2028 - 3rd Watch News

Plaque Psoriasis Treatment Market Poised to Grow at a Healthy CAGR of XX% During the Forecast Period 2017 2025 – Bulletin Line

Evaluation of the Global Plaque Psoriasis Treatment Market

The presented study maps the growth trajectory of the global Plaque Psoriasis Treatment market by thoroughly assessing the various factors that are expected to influence the future prospects of the Plaque Psoriasis Treatment market. According to the report published by PMR, the Plaque Psoriasis Treatment market is poised to attain a value of ~US$ XX Mn/Bn by the end of 2029 with a CAGR growth of ~XX% during the forecast period (2019-2029).

A complete evaluation of the trends, market drivers, opportunities, and challenges faced by market players operating in the Plaque Psoriasis Treatment market is provided in the report. Further, an overview and introduction of the Plaque Psoriasis Treatment market is included to ensure that the readers have a seamless experience while going through the contents of the report.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/16069

Critical insights included in the report:

Competitive Outlook

The competitive outlook assessment provides an in-depth understanding related to the business proceeding of top-tier market players in the global Plaque Psoriasis Treatment market. The product portfolio, sales strategy, marketing & promotional strategy, and sales footprint of each market player is scrutinized thoroughly in the report. Some of the leading players evaluated in the report include:

The report segments the global Plaque Psoriasis Treatment market on the basis of region, product type, and end use.

market players are also exploring the developing market. Novartis launched its Cosentyx in Japan for the treatment of psoriasis arthritis in adults who are not adequately responding to systemic therapy.

Plaque Psoriasis Treatment Market: Market Players

Company manufacturer is converting innovative research into a new therapy by constantly investing in research activities. The number of drugs approved for plaque psoriasis is constantly increasing the number of treatment options for the physician and patients. Eli Lillys interleukin inhibitor was approved by the FDA, second molecule to be approved after Novartis Cosentyx.

Some of the plaque psoriasis treatment market contributors are Allergan, Johnson and Johnson, Amgen, Abbvie, Eli Lilly, Dermira Inc., Novartis, Galectin Therapeutics, Cellceutix Corporation and Biogen Inc., Bayer.

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/16069

Regional Analysis

The market scenario in each region along with a comprehensive assessment of the micro and macro-economic factors that are forecasted to impact the market growth in these regions is included in the report.

End Use Assessment

The market study offers accurate and in-depth analysis of the various end uses of the Plaque Psoriasis Treatment along with a yearly comparison of the market share and revenue growth of each end use.

Important queries addressed in the report:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/16069

Why Opt for PMR?

Originally posted here:

Plaque Psoriasis Treatment Market Poised to Grow at a Healthy CAGR of XX% During the Forecast Period 2017 2025 - Bulletin Line

Systemic Psoriasis Therapeutics Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2020 – Cole of Duty

Insights on the Global Systemic Psoriasis Therapeutics Market

PMR is one of the leading market research companies in India. Our team of research analysts have a deep understanding and knowledge related to the latest market research techniques and use their analytical skills to curate insightful and high-quality market reports. The presented data is collected from credible primary sources including marketing heads, sales managers, product managers, industry experts, and more.

As per the report, the global Systemic Psoriasis Therapeutics market reached a value of ~US$ XX in 2018 and is likely to surpass a market value of ~US$XX by the end of 2029. Further, the report reveals that the Systemic Psoriasis Therapeutics market is set to grow at a CAGR of ~XX% during the forecast period (2019-2029)

Request Sample Report @ https://www.persistencemarketresearch.co/samples/3086

Critical doubts related to the Systemic Psoriasis Therapeutics market addressed in the report:

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/3086

Segmentation of the Systemic Psoriasis Therapeutics market

The report bifurcates the Systemic Psoriasis Therapeutics market into different segments to provide a clear understanding of the various aspects of the market.

Regional Outlook

The regional outlook section of the report includes vital data such as the current trends, regulatory framework, The Systemic Psoriasis Therapeutics market study offers critical data including, the sales volume, sales growth, and pricing analysis of the different products in the Systemic Psoriasis Therapeutics market.

Some of the major companies operating in the global systemic psoriasis therapeutics market are AbbVie Inc., Stiefel Laboratories, Inc., Biogen Idec, Novartis AG, CELGENE CORPORATION, Takeda Pharmaceutical Company Limited, Pfizer Inc., Amgen Inc., Janssen Biotech, Inc. and Eli Lilly and Company.

Key points covered in the report

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/3086

Important insights present in the report:

Read the original post:

Systemic Psoriasis Therapeutics Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2020 - Cole of Duty

Sorting Out the Many Mimickers of Psoriasis – Medscape

Of the many psoriasis mimicker clinicians are likely to encounter, atopic dermatitis is likely the most common one, especially the nummular eczema variant form.

"It has an earlier age of onset, usually in infancy, and can occur with the atopic triad that presents with asthma and seasonal allergies as well,"Israel David "Izzy" Andrews, MD, said at the virtual Pediatric Dermatology 2020: Best Practices and Innovations Conference. "There is typically a very strong family history, as this is an autosomal dominant condition, and it's far more common than psoriasis. The annual incidence is estimated to be 10%-15% of pediatric patients. It has classic areas of involvement depending on the age of the patient, and lesions are intensely pruritic at all times. There is induration and crust, but it's important to distinguish crust from scale. Whereas crust is dried exudate, and scale is usually secondary to a hyperproliferation of the skin. Initially, treatments (especially topical) are similar and may also delay the formalized diagnosis of either of the two."

Another psoriasis mimicker, pityriasis rosea, is thought to be secondary to human herpesvirus 6 or 7 infection, said Dr. Andrews, of the department of dermatology at Phoenix Children's Hospital. It typically appears in the teens and tweens and usually presents as a large herald patch or plaque on the trunk. As the herald patch resolves, smaller lesions will develop on the trunk following skin folds. "It's rarely symptomatic and it's very short-lived, and clears within 6-12 weeks," Dr. Andrews noted. "It can present with an inverse pattern involving the face, neck, and groin, but sparing the trunk. This variant, termed inverse pityriasis rosea, can be confused with inverse psoriasis, which has a similar distribution. However, the inverse pattern of pityriasis rosea will still resolve in a similar time frame to its more classic variant."

Pityriasis lichenoides can also be mistaken for psoriasis. The acute form can present with erythematous, scaly papules and plaques, but lesions are often found in different phases of resolution or healing. "This benign lymphoproliferative skin disorder can be very difficult to distinguish from psoriasis and may require a biopsy to rule in or out," Dr. Andrews said. "It can last months to years and there are few treatments that are effective. It is typically nonresponsive to topical steroids and other treatments that would be more effective for psoriasis, helping to distinguish the two. It is thought to exist in the spectrum with other lymphoproliferative diseases including cutaneous T-cell lymphoma [CTCL]. However, there are only a few cases in the literature that support a transformation from pityriasis lichenoides to CTCL."

Seborrheic dermatitis is more common than atopic dermatitis and psoriasis, but it can be mistaken for psoriasis. It is caused by an inflammatory response secondary to overgrowth of Malassezia yeast and has a bimodal age distribution. "Seborrheic dermatitis affects babies, teens, and tweens, and can persist into adulthood," he said. "Infants with cradle cap usually resolve with moisturization, gentle brushing, and occasional antifungal shampoos." Petaloid seborrheic dermatitis can predominately involve the face with psoriatic-appearing induration, plaques, and varying degrees of scales. "In skin of color, this can be confused with discoid lupus, sarcoidosis, and psoriasis, occasionally requiring a biopsy to distinguish," said Dr. Andrews, who is also an assistant professor of pediatrics at the Mayo Clinic College of Medicine and Science in Scottsdale, Ariz.

Another psoriasis mimicker, pityriasis amiantacea, is thought to be a more severe form of seborrheic dermatitis. It presents with concretions of scale around hair follicles that are highly adherent and are sometimes called sebopsoriasis. "It may be associated with cutaneous findings of psoriasis elsewhere, but may also be found with secondarily infected atopic dermatitis and tinea capitis; however, in my clinical experience, it is most often found in isolation," he said. "There may be a seasonal association with exacerbation in warm temperatures, and treatment often consists of humectants like salicylic acid for loosening scale, topical steroids for inflammation, and gentle combing out of scale."

Infections can also mimic psoriasis. For example, tinea infections are often misdiagnosed as eczema or psoriasis and treated with topical steroids. "This can lead to tinea incognito, making it harder to diagnose either condition without attention to detail," Dr. Andrews said. "On the body, look for expanding lesions with more raised peripheral edges, and central flattening, giving a classic annular appearance. It's also important to inquire about family history and contacts including pets, contact sports/mat sports (think yoga, gymnastics, martial arts), or other contacts with similar rashes." Work-up typically includes a fungal culture and starting empiric oral antifungal medications. "It is important to be able to distinguish scalp psoriasis from tinea capitis to prevent the more inflammatory form of tinea capitis, kerion (a deeper more symptomatic, painful and purulent dermatitis), which can lead to permanent scarring alopecia," he said.

Bacterial infections can also mimic psoriasis, specifically nonbullous impetigo and ecthyma, the more ulcerative form of impetigo. The most frequent associations are group AStreptococcus, methicillin-susceptibleStaphylococcus aureusand methicillin-resistantS. aureus.

Dr. Andrews closed his presentation by noting that tumor necrosis factoralpha inhibitorinduced psoriasiform drug eruptions can occur in psoriasis-naive patients or unmask a predilection for psoriasis in patients with Crohn's disease, juvenile idiopathic arthritis, or other autoinflammatory or autoimmune conditions. "They may improve with continued treatment and resolve with switching treatments," he said. "Early biopsy in psoriasiform drug eruptions can appear like atopic dermatitis on pathology. When suspecting psoriasis in a pediatric patient, it is important to consider the history and physical exam as well as family history and associated comorbidities. While a biopsy may aide in the work-up, diagnosis can be made clinically."

Dr. Andrews reported having no financial disclosures.

This article originally appeared onMDedge.com.

See the rest here:

Sorting Out the Many Mimickers of Psoriasis - Medscape

Global Plaque Psoriasis Treatment Market to Witness Rapid Development During the Period 2017 2025 – Jewish Life News

Plaque psoriasis is a chronic, autoimmune inflammatory disorder which leads to overproduction of skin cells. The skin is characterized by inflamed, raised, scaly, red plaques and lesion. The intensity and frequency of psoriasis are affected by environmental factors such as sun exposure, smoking, HIV infection, and alcoholism. Metabolic syndrome and cardiovascular disease are common in psoriasis patients. Psoriasis increases the chances of myocardial infarction in younger psoriasis patients by three folds.

Moreover, severe psoriasis leads to 3.5 years reduced life expectancy in males relative to individuals without psoriasis. Psoriasis arthritis is a distinct syndrome which occurs in one-third of psoriasis patient with the onset of rheumatic arthritis.

Psoriasis plaque are distinguished by three features, an infiltrate featuring T-cells, the extravagant growth of poorly differentiated keratinocytes and the presence of dilated dermal blood vessels. Most of the introduced therapies for psoriatic were developed as to target T-cells or their inflammatory mediators including cytokines, receptors, and ligands.

Plaque Psoriasis Treatment Market: Dynamics

The demand for plaque psoriasis treatment market is expected to boom with the increasing number of pipeline psoriasis molecule and the number of biologics being launched. Janssen Biotec is seeking for the market approval of Guselkumab. The molecule is in the Phase III trial as a subcutaneous administered therapy for the treatment of plaque psoriasis.

Moreover, Gelantin Therapeutics Inc. announced positive data from its phase 2 study of its drug GR-MD-02 to treat moderate-to-severe plaque psoriasis. The company is now seeking for strategic partnership for its drug development program.

The advent of biologics has also shifted the preference from systemic therapy to meet the existing need. The systemic therapy suppresses the entire immune system as the clinician needs to do routine laboratory monitoring because of myelosuppression, hematologic side effects and increased renal and liver toxicity. Moreover, the systemic therapy is also contraindicated in nursing mothers, pregnant women, and individuals with kidney and liver diseases.

Around 125 million people worldwide have psoriasis out of which 80%, have plaque psoriasis. The need for safe plaque psoriasis therapy in children is essential as about one-third of the psoriasis cases are in children. Etanercept was approved by the DA as an extended indicated for children of age 4 and above.

To remain ahead of your competitors, request for a sample [emailprotected]

https://www.persistencemarketresearch.com/samples/16069

Plaque Psoriasis TreatmentMarket: Segmentation

On the basis therapy the plaque psoriasis treatment market can be segment as:

Phototherapy and systemic therapy should only be used in cases where a topical treatment is inadequate. Novel systemic treatments are now being introduced where a range of biologics are sed. The mode of treatment follows a psoriasis treatment ladder. Initially, topical treatment is given, if the skin fails to respond then phototherapy is given. The third step involves the use of systemic treatment which may be through the administration of pills or injection.

On the basis drug class the plaque psoriasis treatment market can be segment as:

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/16069

TNF- inhibitor was the first class of biologics which were successful in delivering the treatment while still maintaining the safety profile. Enbrel was the first molecule to be approved followed by Remicade and Humira. The introduction of these molecules increased the overall sales of the psoriasis drugs and also increased the physicians comfort and familiarity.

Plaque Psoriasis TreatmentMarket: Region-wise Outlook

North America region dominates the plaque psoriasis market owing to the increasing approval of pipeline drugs and supplemental biologics. In November 2016, the FDA approved supplemental biologics license for the use of Etanercept for children aged four and older having moderate-to-severe plaque psoriasis. The approval is the first of its kind indicated for the treatment of adults with moderate-to-severe plaque psoriasis. Amgen had performed a year-long phase 3 study and 5-year open-label extension testing for the approval.

AsiaPacific is expected to be the fastest-growing region owing to the huge population base and changing lifestyle habits such as smoking. Moreover, the global market players are also exploring the developing market. Novartis launched its Cosentyx in Japan for the treatment of psoriasis arthritis in adults who are not adequately responding to systemic therapy.

You Can Request for TOC Here @

https://www.persistencemarketresearch.com/toc/16069

Plaque Psoriasis TreatmentMarket: Market Players

Company manufacturer is converting innovative research into a new therapy by constantly investing in research activities. The number of drugs approved for plaque psoriasis is constantly increasing the number of treatment options for the physician and patients. Eli Lillys interleukin inhibitor was approved by the FDA, second molecule to be approved after Novartis Cosentyx.

Some of the plaque psoriasis treatment market contributors are Allergan, Johnson and Johnson, Amgen, Abbvie, Eli Lilly, Dermira Inc., Novartis, Galectin Therapeutics, Cellceutix Corporation and Biogen Inc., Bayer.

Read more:

Global Plaque Psoriasis Treatment Market to Witness Rapid Development During the Period 2017 2025 - Jewish Life News

India clears a psoriasis drug for COVID-19, and a tiny US biotech’s shares soar – BioPharma Dive

Dive Brief:

The battle against the new coronavirus is being waged on multiple fronts, from vaccines to prevent infection to other drugs meant to treat and manage COVID-19's many complications.

One of those complications is an overactive immune response, seemingly similar to cytokine release syndrome or CRS, which can cause potentially deadly damage to the lungs or other organs.

Researchers and scientists have been testing other anti-inflammatory drugs against that damaging immune response,but thus far have yet to succeed. The Sanofi and Regeneron arthritis drug Kevzara has failed to deliver a clear benefit in clinical trials, while a similar drug from Roche came up short in a small Italian study after flashing promise earlier.

A larger, more rigorous Actemra trial is still underway, as are tests of the cancer therapies Jakafi and Calquence.

The only drug that has conclusively been shown to reduce death in a large trial of hospitalized COVID-19 patients is the steroid dexamethasone.

But that study, called RECOVERY, didn't look at whether patients where suffering from immune responses characteristic of CRS.Indeed, the mass repurposing of drugs to target COVID-19 related CRS has alarmed some experts, fearful of causing more harm than good.

A JAMAeditorial published in late June highlighted that what is being defined as "cytokine storm" isn't fully understood, and treating those patients with drugs that indiscriminately suppress the immune system "raises concerns about impaired clearance of SARS-CoV-2 and increased risk for secondary infections."

Yet Indian drugmaker Biocon, the developer of plaque psoriasis drug called itolizumab, has claimed success in a study of 30 patients hospitalized with COVID-19 who have CRS and moderate to severe acute respiratory distress syndrome. Bioconreported that in a controlled trial, all 20 people who got itolizumab and standard treatment recovered. Three of the 10 on standard treatment alone died. Decreases in various key markers of inflammation as well as measures of oxygen levels were seen in itolizumab patients as well, according to the company.

Biocon has not provided specifics yet, however, making its claims impossible to fully assess. Still, the results were encouraging enough for the Indian government to clear use of itolizumab in very sick COVID-19 patients. That, along with additional data being generated in Cuba, where the drug was discovered, "could pave the way for discussions with regulators and other government agencies to pursue clinical development and funding in the U.S.," wrote SVB Leerink analyst Thomas Smith.

Results from an open-label, uncontrolled 24-patient study in Cuba currently under a peer review at the journal Immunity & Ageing found that itolizumab appeared to significantly reduce levels of the inflammatory protein IL-6 in the blood. The Cuban government in May also credited the use of itolizumab for an apparent reduction in deaths from COVID-19 among its citizens, though those results didn't come from a randomized, controlled trial.

Unlike Actemra and Kevzara, which inhibit an inflammatory protein called IL-6, Itolizumab blocks CD6, a protein found on the surface of many immune cells, among them effector T cells that drive inflammation in a variety of diseases. The drug was approved in India in 2013 to treat chronic plaque psoriasis under the brand name Alzumab. Equillium has since licensed rights in the U.S., Canada, New Zealand and Australia and has been aiming to develop it for a number of inflammatory conditions like asthma and lupus.

In light of the news from India, Equillium said it plans to ask the Food and Drug Administration to start a global randomized trial of itolizumab. Equillium shares more than doubled, to over $8 apiece, though that's still less than the $14 per share price at which the company went public in 2018.

Equillium had to stall testing of itolizumab which it calls EQ001 due to the pandemic. But it said Monday that those trials have now resumed.

Excerpt from:

India clears a psoriasis drug for COVID-19, and a tiny US biotech's shares soar - BioPharma Dive

SkinBioTherapeutics targets the promising skin microbiome market – Proactive Investors UK

The life sciences firm studies how to enhance and reintroduce the good bacteria on the skin

() has set out to make the skin feel and look better by studying the bacteria that live on its surface.

While most people know about the importance of having a healthy gut microbiome, the benefits of reinforcing good bacteria [probiotics] to the skin are yet to be discovered by the wider public.

But its a promising path: according to a Fortune Business Insights, the global probiotics market will reach US$74.7bn by the end of 2025 and the skin is going to be at the forefront of this growth.

The life sciences firm was spun out from () in 2015 and Opti remains the majority shareholder with a 29.8% stake.

SkinBioTherapeutics proprietary technology SkinBiotix is patented in various countries and based on studies conducted by Catherine ONeill and Andrew McBain at The University of Manchester.

The AIM-listed company is exploring five avenues of development: medical biotics; pharmabiotics; access biotics; cosmetics; and cleanbiotics.

Medical focuses on wound healing while pharma is analysed for prescribed treatment for skin conditions.

The two have a longer development path due to the regulatory hurdles to be crossed.

Access biotics, though, has recently passed major milestone through a partnership with Dutch firm Winclove Probiotics to develop a food supplement to alleviate symptoms of psoriasis.

The product, called AxisBiotix, may be ready for the shelves within a year.

The pair, which started collaborating in February, have already came up with the first formulation and are ready to enter a study on humans eight months ahead of schedule.

The whole access biotics project is to look at the pathways, what happens in the gut and how it manifests on the skin, so there are multiple places we could have started from, eczema, acne or psoriasis, chief executive Stuart Ashman told Proactive.

We chose psoriasis because its a particularly aggressive condition, it affects about 3% of the global population and there is no cure.

Many sufferers have had to enter complete coronavirus isolation because they take immunosuppressants to control the psoriasis outbreaks.

During a global pandemic the last thing in the world is suppress your immune system, you actually want that firing on all cylinders, so we firmly believe that its very, very important to get this into the community as quickly as possible, Ashman added.

Elsewhere,Ashmans team have been working with speciality chemical producer () since November to design and manufacture ingredients for the cosmetics market.

The initial target was enhancing the barrier effect of the skin to stop infections, but during the human safety studies the researchers came across significant anti-ageing indications, too.

The life sciences firm is providing its technology to the FTSE 100 companys unit Sederma, while SkinBioTherapeutics gets access to Sedermas huge base of customers, including prestigious brands such as Chanel, Garnier and LOreal.

Sederma has slowly restarted operations following a halt at the beginning of lockdowns, though there has been no material delay on their joint work.

Finally, infection control in both the home and the hospital environment has also taken on a new degree of urgency following the COVID-19 outbreak.

The skin is a very complicated surface, but it is just a surface, so we are doing the same thing on a non-living surfaces such as an operating table or bedsheets, explained Ashman.

In this application, the scientists are looking at how they can prevent the latching of bad bacteria onto surfaces.

Looking at the numbers, SkinBioTherapeutics is currently in the research and development phase, so its still pre-revenue.

First sales are estimated to come in around two years, which would be November 2021 for the deal with Croda and February 2022 for Winclove, although the timeline for the latter has now compressed significantly.

Cash at the end of June was around 2.1mln.

At current cash burn we do have a two-year window however, as we commence commercialisation and we start new rapid access trials, we will start burning cash a little faster, Ashman concluded.

Its going to be very busy. Regardless of what Covid-19 throws at us, we are looking to find all routes possible to get this psoriasis product into the hands of those that need it and progress on the other areas.

At 19.4p, the company is valued at 25mln.

More here:

SkinBioTherapeutics targets the promising skin microbiome market - Proactive Investors UK

Scientific Solution for Sensitive Skin: Perricone MD Announces New Hypoallergenic CBD Sensitive Skin Therapy Collection – PRNewswire

SAN FRANCISCO, July 13, 2020 /PRNewswire/ -- Perricone MD continues its dedication to breakthrough, science-backed skincare solutions with a new collectionfeaturing 99% pure Cannabidiol (CBD), sourced in the United States, as the featured active ingredient. Drawing from loyal brand fan requests for a true sensitive skin care line, Perricone MD took innovation with CBD to the next level with the introduction of the Hypoallergenic CBD Sensitive Skin Therapy Collection.

Known for its soothing and calming benefits, CBD is a naturally-derived, powerful antioxidant that helps revitalize the look of stressed and problematic skin. Unlike other CBD products on the market, Perricone MD intentionally innovates with 99% Cannabidiol isolate to embrace the powerful ingredient in its most potent and pure form for maximum benefits. Other brands often use full- and broad-spectrum CBD, which contain impurities. With the combination of 99% pure Cannabidiol and other clean ingredients like Buriti Oil and Cherimoya Fruit Extract, this ultra-gentle regimen provides the ultimate relief for angry, irritated skin.

"We have led the category with CBD skincare innovation since 2017, first with our CBx for Men franchise, then with the addition of CBD to our Cold Plasma Plus+ Advanced Serum Concentrate in early 2020. As the ingredient has become more mainstream and widely accepted, we have decided to expand our portfolio through the introduction of Hypoallergenic CBD Sensitive Skin Therapy," says Robert Koerner, Perricone MD's Chief Marketing Officer. "We consistently hear from customers experiencing irritation that ultimately takes a toll on the skin's appearance, resulting in stressed and problematic texture. We are thrilled to be able to offer the collection as an effective solution for the angriest, stressed and irritated skin."

Recognized and approved by the National Psoriasis Foundation, the regimen is also suitable for individuals living with psoriasis and other severe sensitive skin conditions. "The National Psoriasis Foundation Seal of Recognition identifies products that have been created or are intended to be non-irritating and safe for people living with psoriasis and psoriatic arthritis," said Stacie Bell, Ph.D., chief scientific and medical officer, National Psoriasis Foundation. "With the addition of these products, we are excited to offer our psoriasis patient community an expanded number of quality products recognized to soothe symptoms specific to psoriasis."

Specifically developed for those with sensitive skin, the collection is non-comedogenic, dermatologist-tested and free of the 26 known allergens as well as fragrance, gluten, sulfates, silicones, parabens, formaldehyde, butylene- and propylene-glycol, PEG, phthalates, BHA and BHT.

The four-piece collection consists of the following:

Boasting impressive clinical results, the four-week study on the regimen showed improvement to skin barrier function, radiance, hydration, texture, tightness and elasticity. Additionally, the overall appearance of crepiness, fines lines and wrinkles was reduced**.

The Hypoallergenic CBD Sensitive Skin Therapy Collection is now available onSootheskin.PerriconeMD.com, available at Ulta Beauty, Ulta.com, Dillards.com, Macy's, Macys.com, EC Scott and ECScottgroup.com by early August.

*Based on a consumer study on 102 people over 28 days.**Based on a clinical study with 40 females over 28 days after using the full collection.

About Perricone MD

We Pick Up Where Nature Left Off.For over two decades, Perricone MD has been based around a three-tier, holistic skin and wellness system. It consists of an anti-inflammatory diet, essential dietary supplements and potent topical skincare solutions backed by some of the most powerful ingredients on the planet. Perricone MD was created by Dr.Nicholas Perricone, whoseNew York Timesbest-sellerThe Wrinkle Cureintroduced the world to the benefits of an anti-inflammatory lifestyle.Perricone MD is driven by the pursuit of fearless innovation and a stubbornly uncompromising spirit of excellence."We continuously seek the truth in unlocking the powerful science behind healthy-looking skin, from the inside out and outside in."

Perricone MD products feature some of the most potent ingredients on the planet that replenish the building blocks of healthy-looking skin, picking up where nature left off. The brand's award-winning patented sciences include: H2 Energy Complex, Nrf2 Antioxidant Support Complex, DMAE, Alpha Lipoic Acid, Vitamin C Ester, Acyl-Glutathione, and Neuropeptides. Perricone MD products are available onPerriconeMD.com, as well as UltaBeauty, Nordstrom, Dillard's, Lord & Taylor,Neiman Marcus, QVC and Sephora, and other leading specialty stores in the US. Perricone MD products are also available in more than 34 countries around the world in prestige retailers.

SOURCE Perricone MD

http://PerriconeMD.com

View original post here:

Scientific Solution for Sensitive Skin: Perricone MD Announces New Hypoallergenic CBD Sensitive Skin Therapy Collection - PRNewswire

More SAEs With Biologic Agents vs Placebo in Treatment of Psoriasis – Dermatology Advisor

The exclusion of patients with worsening psoriasis from meta-analyses of trials that examine biologic therapies for type-plaque psoriasis reveal that serious adverse events (SAEs) are higher with biologic therapies than placebo, which suggest that findings from many meta-analyses do not reflect the real-world safety of biologic agents for psoriasis. This is according to a study research published in the British Journal of Dermatology.

In this study, researchers from France analyzed 51 randomized clinical trials in the Living Network Cochrane Review that compared a biologic therapy to placebo in patients with moderate to severe plaque psoriasis who required systemic treatment (N=24,820).

Trials included in this analysis included 1 anti-tumor necrosis factor (TNF) alpha arm, 1 anti-interleukin (IL)-17 arm, 1 anti-IL-23 arm, and 1 anti-IL-12/23 arm. The primary outcome of the analysis included the number of SAEs with biologic agents vs placebo after cases of psoriasis worsening were excluded. An additional secondary outcome included the number of adverse events (AEs) of special interest.

The mean age of the overall population was 45 years, and the mean baseline PASI score was 20.5. A higher percentage of patients included in all 51 trial were men compared with women (69% vs 31%, respectively). Approximately 25% (n=6287) of the population were randomly assigned to a placebo group.

In the analysis that included cases of psoriasis worsening, there was no statistically significant difference between biologic therapies and placebo in terms of the risk for occurrence SAEs (risk ratio [RR], 1.09; 95% CI, 0.88-1.36; P =.43). When the investigators excluded cases of psoriasis worsening, however, biologicl therapy was associated with a significantly higher risk for SAEs (RR, 1.30; 95% CI, 1.02-1.65; P =.03).

Separated by drug classes, the analysis revealed RRs of 1.68 (95% CI, 1.11-2.54; P =.01) for anti-TNF-alpha, 1.28 (95% CI, 0.88-1.85; P =.20) for anti-IL-17, 0.95 (95% CI 0.59-1.52; P =.83) for anti-IL-23, and 1.18 (95% CI 0.72-1.94; P =.51) for anti-IL-12/23. The small number of AEs of special interest in these analyses prevented the researchers from examining this outcome.

According to the investigators, the reporting of psoriasis worsening has changed over time, which made indirect comparisons not possible by network meta-analysis.

Based on these findings, the investigators added that the results for SAEs overall and SAEs excluding disease worsening should be presented in the results of RCTs and so in systematic reviews and meta-analyses.

Reference

Afach S, Chaimani A, Evrenoglou T, et al. Meta-analysis results do not reflect the real safety of biologics in psoriasis [published online May 23, 2020]. Br J Dermatol. doi: 10.1111/bjd.19244

Read this article:

More SAEs With Biologic Agents vs Placebo in Treatment of Psoriasis - Dermatology Advisor

DCGI approves limited use of psoriasis injection for Covid-19 – Hindustan Times

DCGI approves limited use of psoriasis injection for Covid-19 - india news - Hindustan Times "; forYoudata += ""; forYoudata += ""; forYoudata += ""; count++; if (i === 7) { return false; } }); forYouApiResponse=forYoudata; $(forutxt).html('Recommended for you'); $(foruContent).html(forYoudata); } } }); } else if(forYouApiResponse!=''){ $(forutxt).html('Recommended for you'); $(foruContent).html(forYouApiResponse); } } function getUserData(){ $.ajax({ url:"https://www.hindustantimes.com/newsletter/get-active-subscription?usertoken="+user_token, type:"GET", dataType:"json", success: function(res){ if(res.length>0) { $("[id^=loggedin]").each(function(){ $(this).hide(); }); } } }); } function postUserData(payLoad, elm){ var msgelm=$(elm).parents(".subscribe-update").nextAll("#thankumsg"); $.ajax({ url:"https://www.hindustantimes.com/newsletter/subscribe", type:"POST", data:payLoad, contentType: "application/json", dataType: "json", success: function(res){ if(res.success===true){ $(msgelm).show(); $("[id^=loggedin]").each(function(){ $(this).css("display","none"); }); $("[id^=loggedout]").each(function(){ $(this).css("display","none"); }); } else if(res.exceptionResponse.alreadySubscribed===true){ $(msgelm).show(); $("[id^=loggedin]").each(function(){ $(this).css("display","none"); }); $("[id^=loggedout]").each(function(){ $(this).css("display","none"); }); $(msgelm).find(".subscribed-successfully:first span.msg").text(res.exceptionResponse.message); } } }); }function captchverification(captchaResponse) {$('#captchaResponse').value = captchaResponse;$("#captcha-div").removeClass("block");$("body").removeAttr("style");var payLoad=JSON.stringify({ "domain": "HT", "emailId": email, "googleCaptcha": captchaResponse, "subscriptionTypes": [ "daily" ] });postUserData(payLoad,activeElm);} function subscribeNewsletter(inputText) { activeElm=inputText; var mailformat = /^w+([.-]?w+)*@w+([.-]?w+)*(.w{2,3})+$/; if(inputText.val().match(mailformat)) { inputText.focus(); email=inputText.val(); $("#captcha-div").addClass("block"); $("body").css("overflow","hidden"); return true; } else { alert("You have entered an invalid email address!"); inputText.focus(); return false; } } //DFP Ads var $dfpRightAd1 = $('.dfp-rightAd1-' + storyUuid); var $dfpRightAd2 = $('.dfp-rightAd2-' + storyUuid); var $dfpRightAd3 = $('.dfp-rightAd3-' + storyUuid); var $dfpRightAd4 = $('.dfp-rightAd4-' + storyUuid); var $dfpRightAd5 = $('.dfp-rightAd5-' + storyUuid); var $dfpStoryAd1 = $('.dfp-storyAd1-' + storyUuid); var $dfpStoryAd2 = $('.dfp-storyAd2-' + storyUuid); var $dfpStoryAd3 = $('.dfp-storyAd3-' + storyUuid); var $dfpStoryAd4 = $('.dfp-storyAd4-' + storyUuid); var $dfpStoryAd5 = $('.dfp-storyAd5-' + storyUuid); var $centerAd = $('.centerAd-' + storyUuid); getPersonlizeData(''); displayAd($dfpRightAd1,'/1055314/HT_StoryPages_300x250_Top',[[300, 250], [300, 600]]); displayAd($dfpRightAd2,'/3106570/HT_Desk_Story_BS_Multisize',['fluid', [300, 100]]); var rightMiddleScrollHandler = function () { if ($dfpRightAd3.isInViewport()) { displayAd($dfpRightAd3, '/1055314/HT_StoryPages_300x250_Middle', [[300, 250], [300, 600]]); $(window).off("scroll", rightMiddleScrollHandler); } } $(window).on("scroll", rightMiddleScrollHandler); var rightTabRepTopScrollHandler = function () { if ($dfpRightAd4.isInViewport()) { displayAd($dfpRightAd4, '/1055314/HT_Desk_Story_TabRep_Top_Multisize', [[300, 250], [300, 600]]); $(window).off("scroll", rightTabRepTopScrollHandler); } } $(window).on("scroll", rightTabRepTopScrollHandler); var rightTabRepBottomScrollHandler = function () { if ($dfpRightAd5.isInViewport()) { displayAd($dfpRightAd5, '/1055314/HT_Desk_Story_TabRep_Bottom_Multisize', [300, 250]); $(window).off("scroll", rightTabRepBottomScrollHandler); } } $(window).on("scroll", rightTabRepBottomScrollHandler); var storyCenterScrollHandler = function () { if ($centerAd.isInViewport()) { displayAd($centerAd, '/1055314/HT_Desk_Story_ES_Top_728x90', [728, 90]); $(window).off("scroll", storyCenterScrollHandler); } } $(window).on("scroll", storyCenterScrollHandler); //Inline story ads var storyAd1ScrollHandler = function () { if ($dfpStoryAd1.isInViewport()) { displayAd($dfpStoryAd1, storyAdList[0].ad, [728, 90]); $(window).off("scroll", storyAd1ScrollHandler); } } $(window).on("scroll", storyAd1ScrollHandler); var storyAd2ScrollHandler = function () { if ($dfpStoryAd2.isInViewport()) { displayAd($dfpStoryAd2, storyAdList[1].ad, [728, 90]); $(window).off("scroll", storyAd2ScrollHandler); } } $(window).on("scroll", storyAd2ScrollHandler); var storyAd3ScrollHandler = function () { if ($dfpStoryAd3.isInViewport()) { displayAd($dfpStoryAd3, storyAdList[2].ad, [728, 90]); $(window).off("scroll", storyAd3ScrollHandler); } } $(window).on("scroll", storyAd3ScrollHandler); var storyAd4ScrollHandler = function () { if ($dfpStoryAd4.isInViewport()) { displayAd($dfpStoryAd4, storyAdList[3].ad, [728, 90]); $(window).off("scroll", storyAd4ScrollHandler); } } $(window).on("scroll", storyAd4ScrollHandler); var storyAd5ScrollHandler = function () { if ($dfpStoryAd5.isInViewport()) { displayAd($dfpStoryAd5, storyAdList[4].ad, [728, 90]); $(window).off("scroll", storyAd5ScrollHandler); } } $(window).on("scroll", storyAd5ScrollHandler); validateUser($("#loggedin"),$("#loggedout")); if(user_token){ $("#loggedin .subscribe-text").html("Subscribe to get our daily newsletter in your inbox"); $("#loginSub").click(function(){ var udata=JSON.stringify({ "domain": "HT", "userToken": user_token, "googleCaptcha": "string", "subscriptionTypes": [ "daily" ] }); postUserData(udata,this); }); }else{ $("#loggedout .subscribe-text").html("Enter your email to get our daily newsletter in your inbox"); $("#subscribeBtn").click(function(){ subscribeNewsletter($(this).prev()); }); } function ScrollMe(uuid) {var id = uuid.replace('story_','').trim(); id = id +"_story";var newid = uuid.trim();$('#ulInfinite').each(function() {var phrase = '';$(this).find('li').each(function(j, lix) {var myid = $(lix).attr('id');if (myid.trim() == newid.trim())$(lix).addClass("active");else$(lix).removeClass("active");});});var element = document.getElementById(id);element.scrollIntoView();element.scrollIntoView({behavior : "auto",block : "start",inline : "nearest"});$('html, body').animate({scrollTop : $("#" + newid).offset().top - 800}, 800, 'swing');}function InfiniteScroll() {var nextURL = listUrl[urlCount];var $container = $('.articles').infiniteScroll({path : function() {return nextURL;},append : '.article',status : '.scroller-status',hideNav : '.pagination',loadOnScroll : false,scrollThreshold : false});$container.infiniteScroll('loadNextPage');$container.on('history.infiniteScroll', function(event, title, path) {var currentID = "article_" + getStoryIdByUrl('https://www.hindustantimes.com/india-news/dcgi-approves-limited-use-of-psoriasis-injection-for-covid/story-bkVPzdJ7Y9oaCiX2NJkypO.html');var articleID = "article_" + getStoryIdByUrl(path);document.title = title;var temp = path.replace('.html', '').split('-');temp = temp.reverse();var forNid = temp[0].trim();$('#ulInfinite li').removeClass("active");$('#story_' + forNid).addClass("active");var n = gatag.includes(articleID, 0);if(n==false){gatag.push(articleID);showSkippablePopup();ga('send', {hitType : 'pageview',location : window.location.hostname.trim(),title : title.trim(),page : window.location.pathname.trim(),dimension15 : title});}window.snowplow("trackPageView", title);window.snowplow('resetPagePing');if (typeof COMSCORE != 'undefined'&& typeof COMSCORE.beacon !== 'undefined') {COMSCORE.beacon({c1 : "2",c2 : "6035286"});}});$container.on('load.infiniteScroll', function(event, response, path) {urlCount++;});var counter = 1;var uuid;$container.on('append.infiniteScroll', function(event, response, path, items) {uuid= $(items).find('.get-uuid').val();var elmLogin=$(items).find('#loggedin');var elmLogout=$(items).find('#loggedout');getPersonlizeData(items); validateUser(elmLogin,elmLogout); if(user_token){ getUserData(); $(elmLogin).find(".subscribe-text").html("Subscribe to get our daily newsletter in your inbox"); $(items).find("#loginSub").click(function(){ var udata=JSON.stringify({ "domain": "HT", "userToken": user_token, "googleCaptcha": "string", "subscriptionTypes": [ "daily" ] }); postUserData(udata, this); }); }else{ $(elmLogout).find(".subscribe-text").html("Enter your email to get our daily newsletter in your inbox"); $(items).find("#subscribeBtn").click(function(){ subscribeNewsletter($(this).prev()); }); }var $dfpRightAd1ES = $(items).find('.dfp-rightAd1-'+uuid); var $dfpRightAd3ES = $(items).find('.dfp-rightAd3-'+uuid); var $dfpRightAd4ES = $(items).find('.dfp-rightAd4-'+uuid); var $dfpRightAd5ES = $(items).find('.dfp-rightAd5-'+uuid); var $centerAdES = $(items).find('.centerAd-' + uuid); var $dfpStoryAd1ES = $('.dfp-storyAd1-' + uuid);var $dfpStoryAd2ES = $('.dfp-storyAd2-' + uuid); var $dfpStoryAd3ES = $('.dfp-storyAd3-' + uuid); var $dfpStoryAd4ES = $('.dfp-storyAd4-' + uuid); var $dfpStoryAd5ES = $('.dfp-storyAd5-' + uuid); var isVideoExists = $(items).find('.video-js'); var isVideo=false; if (isVideoExists.length > 0) { isVideo=true; } var rightESTopScrollHandler = function () { if ($dfpRightAd1ES.isInViewport()) { displayAd($dfpRightAd1ES, rightAdList[0].ad, rightAdList[0].adsizes); $(window).off("scroll", rightESTopScrollHandler); } } $(window).on("scroll", rightESTopScrollHandler); var rightESMiddleScrollHandler = function () { if ($dfpRightAd3ES.isInViewport()) { displayAd($dfpRightAd3ES, rightAdList[1].ad, rightAdList[1].adsizes); $(window).off("scroll", rightESMiddleScrollHandler); } } $(window).on("scroll", rightESMiddleScrollHandler); var rightESTabRepTopScrollHandler = function () { if ($dfpRightAd4ES.isInViewport()) { displayAd($dfpRightAd4ES, rightAdList[2].ad, rightAdList[2].adsizes); $(window).off("scroll", rightESTabRepTopScrollHandler); } } $(window).on("scroll", rightESTabRepTopScrollHandler); var rightESTabRepBottomScrollHandler = function () { if ($dfpRightAd5ES.isInViewport()) { displayAd($dfpRightAd5ES, rightAdList[3].ad, rightAdList[3].adsizes); $(window).off("scroll", rightESTabRepBottomScrollHandler); } } $(window).on("scroll", rightESTabRepBottomScrollHandler); var storyCenterScrollHandler = function () { if ($centerAdES.isInViewport()) { displayAd($centerAdES, '/1055314/HT_Desk_Story_ES_Top_728x90', [728, 90]); $(window).off("scroll", storyCenterScrollHandler); } } $(window).on("scroll", storyCenterScrollHandler); //Story Inline ads var storyESAd1ScrollHandler = function () { if ($dfpStoryAd1ES.isInViewport()) { displayAd($dfpStoryAd1ES, storyAdList[0].ad2, [728, 90]); $(window).off("scroll", storyESAd1ScrollHandler); } } $(window).on("scroll", storyESAd1ScrollHandler); var storyESAd2ScrollHandler = function () { if ($dfpStoryAd2ES.isInViewport()) { displayAd($dfpStoryAd2ES, storyAdList[1].ad2, [728, 90]); $(window).off("scroll", storyESAd2ScrollHandler); } } $(window).on("scroll", storyESAd2ScrollHandler); var storyESAd3ScrollHandler = function () { if ($dfpStoryAd3ES.isInViewport()) { displayAd($dfpStoryAd3ES, storyAdList[2].ad2, [728, 90]); $(window).off("scroll", storyESAd3ScrollHandler); } } $(window).on("scroll", storyESAd3ScrollHandler); var storyESAd4ScrollHandler = function () { if ($dfpStoryAd4ES.isInViewport()) { displayAd($dfpStoryAd4ES, storyAdList[3].ad, [728, 90]); $(window).off("scroll", storyESAd4ScrollHandler); } } $(window).on("scroll", storyESAd4ScrollHandler); var storyESAd5ScrollHandler = function () { if ($dfpStoryAd5ES.isInViewport()) { displayAd($dfpStoryAd5ES, storyAdList[4].ad, [728, 90]); $(window).off("scroll", storyESAd5ScrollHandler); } } $(window).on("scroll", storyESAd5ScrollHandler); counter++;if (urlCount = n && o = n ? t.play() : t.pause()) : console.log("iOS") }) }); }}else if(isVideo){$(items).find("video[id^='myPlayerID_']").each(function(t, e) {var n = "myPlayerID_" + $(e).attr("data-video-id");bc(n), videojs(n).ready(function() {this.scrollIntoView()}) });}$(items).find("div[id^='right-swiper-']").each(function(i, e) {var swipID = $(e).attr("id");var storySwiper = new Swiper('#' + swipID, {pagination : {el : '.swiper-pagination',clickable : true},preloadImages : false,lazyLoading : true,simulateTouch : false,autoplay : {delay : 3000,}});});var ind = 0;$(items).find('.read-more').each(function(ind, obj) {ind = ind + 1;var html = $(items).find("#inlineStory" + ind).html();$(this).html(html);});$(items).find('img.lazy').each(function(i, e) {$(e).lazyload({effect : "fadeIn",effectTime : 20,threshold : 200,failurelimit : 0});});//getSeoContent(items);});}var reqOpen = true;$(document).bind("scroll",function() {var viewport = {top : $(document).scrollTop(),left : $(document).scrollLeft()};viewport.bottom = viewport.top + $(document).height();lastScrollTop = viewport.top;var bot = viewport.bottom - $(document).height();if (viewport.top > 200 && (showInfinite)) {if(isCorona && !loaded){var s= document.createElement('script');s.setAttribute('async','');s.src="https://chat.amplify.ai/plugin/5e77327dd8722a5cf17170be/chat_plugin.js?pluginId=5e77327dd8722a5cf17170be";document.getElementsByTagName('head')[0].appendChild(s);loaded=true;}$('.footer-scroll-main').show();if (reqOpen == true) {$('#ulInfinite li:first').addClass("active");$('#ulInfinite li .stroy-link').each(function(i, t) {if(i>0){listUrl.push($(t).html());}});InfiniteScroll();reqOpen = false;} } else if (bot

See more here:

DCGI approves limited use of psoriasis injection for Covid-19 - Hindustan Times

Market Players Eye Opportunities in Emerging Economies to Gain Ground in the Chronic Plaque Psoriasis Therapeutics Market 2017 2025 – Jewish Life…

The global Chronic Plaque Psoriasis Therapeutics market gives detailed Evaluation about all of the Important aspects related to the market. The study on international Chronic Plaque Psoriasis Therapeutics economy, offers deep insights regarding the Chronic Plaque Psoriasis Therapeutics market covering all of the crucial aspects of the marketplace. Moreover, the report provides historical information with prospective forecast over the forecast period. Various important factors like market trends, revenue growth patterns market stocks and supply and demand are contained in almost all the market research document for every business. A number of the important aspects analysed in the report contains market share, creation, key regions, revenue rate as well as key players.

The study of various sections of the international market are also Covered in the research report. In addition to that, for the forecast periods conclusion of factors such as market size and the competitive landscape of the market is analysed in the report. Due to the rising globalization and digitization, there are new trends coming to the marketplace daily. The research report provides the detailed analysis of all of these tendencies.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/21442

In addition, the Chronic Plaque Psoriasis Therapeutics marketplace report also supplies the Latest trends in the global Chronic Plaque Psoriasis Therapeutics market with the assistance of primary in addition to secondary research methodologies. Also, the analysis report on Chronic Plaque Psoriasis Therapeutics market gives a wide analysis of the market including market overview, production, manufacturers, dimensions, price, value, growth rate, income, prices, export, consumption, and sales revenue of this global Chronic Plaque Psoriasis Therapeutics market. On the other hand, the Chronic Plaque Psoriasis Therapeutics market report also studies the market status for the prediction period. However, this will help to grow the advertising opportunities throughout the world as well as major market suppliers.

The key manufacturers engaged in developing the chronic plaque psoriasis therapeutics market include Abbvie, Inc., Novartis International AG, Pfizer, Inc., Merck & Co., Astelllas Pharma, Inc., GlaxoSmithKline Plc and others.

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/21442

The Chronic Plaque Psoriasis Therapeutics market report provides helpful insights for Every established and innovative players throughout the globe. Additionally the Chronic Plaque Psoriasis Therapeutics market report provides accurate evaluation for the shifting competitive dynamics. This study report includes a complete analysis of future growth in terms of the evaluation of the mentioned forecast period. The Chronic Plaque Psoriasis Therapeutics market report offers a comprehensive analysis of the technological advancement prognosis over time to be aware of the market growth prices. The Chronic Plaque Psoriasis Therapeutics market report also has progressive analysis of the huge number of unique facets which are boosting or operating in addition to regulating the Chronic Plaque Psoriasis Therapeutics market growth.

A systematized methodology can be utilized to create a Report on the Global Chronic Plaque Psoriasis Therapeutics market. For the research of economy on the Conditions of study Approaches, these techniques are useful. All of the Information Regarding this Products, makers, vendors, clients and much more is covered in research reports. Various important factors like market trends, revenue Growth patterns market stocks and demand and supply are included in virtually all The market study report for every industry. Adaptation of fresh ideas and Accepting the most recent trends are a few the reasons for virtually any markets growth. The Global Chronic Plaque Psoriasis Therapeutics market research report provides the profound understanding about the Regions in which the marketplace is impactful.

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/21442

Read more from the original source:

Market Players Eye Opportunities in Emerging Economies to Gain Ground in the Chronic Plaque Psoriasis Therapeutics Market 2017 2025 - Jewish Life...

Global Dermatology Biologics Market Revenue to Witness Rapid Growth in the Near Future – Jewish Life News

Dermatology biologics refers to agents synthesized from the products of living organisms which are used for dermatologic treatment. Every year, several million people are affected by skin-related diseases across the world. Dermatology biologics are becoming significantly beneficial over conventional system therapies due to their target-specific mechanism. Dermatology biologics target specific sites in the immune-pathogenesis pathway of the disease. Dermatology biologics are widely used for the treatment of severe psoriasis, psoriatic arthritis, other types of arthritis and inflammatory bowel diseases. These biologics have revolutionized the treatment of various dermatologic diseases. The first biologic for the treatment of these diseases was approved in 2003, today there are 10 FDA approved biologics in the market to treat moderate to severe plaque psoriasis, which is expected to increase the demand of dermatology biologics over the forecast period.

To remain ahead of your competitors, request for a sample [emailprotected] https://www.persistencemarketresearch.com/samples/23005

Dermatology Biologics Market: Drivers and Restraint

Dermatology Biologics market will witness promising growth due to rising prevalence of chronic diseases. Introduction of various innovative products in the form of dermatology biologics and drug-releasing implants, as a result of research and development and continuous efforts to invent treatment alternatives, are also contributing to market growth. Efficiency and target specific approach of dermatology biologics and high adoption rate of dermatology biologics in psoriasis treatment are the other driving factors for the market growth. However, the availability of a limited number of dermatology biologics, stringent regulatory norms associated with the approval of dermatology biologics, severe side effects of dermatology biologics and expensive nature of dermatology biologics may hamper the dermatology biologics market growth during the forecast period.

To receive Methodology request here@ https://www.persistencemarketresearch.com/methodology/23005

Dermatology Biologics Market: Segmentation

The global market for Dermatology Biologics can be segmented on the basis of product type, indication, distribution channel and geography:

Dermatology Biologics Market: Overview

The global dermatology biologics market is witnessing rapid growth due to the emergence of innovative dermatology biologics in recent years. The FDA recently approved Janssens guselkumab (Tremfya) for the treatment of plaque psoriasis. The overall market is expected to report promising growth as the epidemiologic studies have revealed that prevalence of psoriasis in the UK is estimated to be at 1.3%2.2%. Promising revenue growth is expected in the dermatology biologics market during the forecast period due to the introduction of novel dermatology biologics products in near future.

To receive extensive list of important regions, Request TOC here @ https://www.persistencemarketresearch.com/toc/23005

Dermatology Biologics Market: Region-wise Outlook

On the basis of geography, the global Dermatology Biologics market is segmented into six key regions North America, Latin America, Europe, Asia Pacific excluding China and Middle East & Africa. North America followed by Europe will continue to dominate the global dermatology biologics market in terms of revenue owing to rising technological advancements in healthcare and systematic drug review processes. The Europe dermatology biologics market is driven by growing funding for the development of dermatology biologics available through public-private partnerships, availability of high-quality research infrastructure and innovative strategies being developed by drug makers. Furthermore, rising disease incidences in emerging countries are expected to prove to be favorable for the growth of the dermatology biologics market

Dermatology Biologics Market: Key Market Participants

The key market players in the global Dermatology Biologics market include Pfizer Inc., AstraZeneca, Genzyme, Merck KGaA., Johnson & Johnson, Amgen, Valeant Pharmaceuticals International, Inc. and other and others. The key players have indulged in strategic initiatives, such as collaborations, acquisitions and mergers and product launches in the recent years.

Excerpt from:

Global Dermatology Biologics Market Revenue to Witness Rapid Growth in the Near Future - Jewish Life News

Research Associate/Senior Research Associate in Molecular Epidemiology job with UNIVERSITY OF BRISTOL | 213189 – Times Higher Education (THE)

Division/SchoolBristol Medical SchoolContract typeOpen EndedWorking patternFull or Part timeSalary33,797 to 38,017 Grade I / 38,017 to 42,792 Grade J per annumClosing date for applications09-Aug-2020

We are seeking to appoint a Research Associate/Senior Research Associate in molecular epidemiology/bioinformatics to analyse genomic data generated by Biomarkers in Atopic Dermatitis and Psoriasis (BIOMAP,https://www.biomap-imi.eu/).

The post-holder will be a key member of the BIOMAP work package 3 data analysis team (https://www.biomap-imi.eu/about/work-packages) to determine causal relationships between intermediate omics traits and Atopic Dermatitis and Psoriasis subtypes to identify potential target mechanisms. The postholder will perform comprehensive analysis of DNA methylation and gene expression data using blood and skin samples from multiple cohorts in order to link molecular signatures to Atopic Dermatitis and Psoriasis subtypes. They will examine the identified associations over the life course using longitudinal data and will use Mendelian Randomization, to determine which EWAS/TWAS associations have causal evidence. They will also use Bayesian colocalization analysis to identify the likely causal genes implicated by GWAS of Atopic Dermatitis and Psoriasis subtypes and compare molecular signatures in isolated cell types to determine the tissue/cell type-specific regulatory component of differentially expressed/methylated signatures. Feature selection methods will also be used to predict Atopic Dermatitis and Psoriasis subtypes.

The postholder will be part of the MRC Integrative Epidemiology Unit (IEU) at the University of Bristol and will be aligned with multiple programmes (epigenetic epidemiology and Mendelian randomization) within the unit. The work undertaken in this position will be driven by the objectives of BIOMAP, however will allow (and encourage) the development of a personal research portfolio.

The appointment will be at Grade I or J, dependant on the extent of relevant research experience, is offered as an open ended contract with 3 years initial funding. This could be on a full-time or part-time basis, or could allow time to be split with another project. The post is ideally suited to someone with a PhD in molecular epidemiology, bioinformatics or a closely related discipline. You will have experience using statistical programming languages (such as R) and preferably experience of working with large-scale molecular datasets. You will have experience of applied statistical analysis and understanding of EWAS, TWAS and preferably also Mendelian randomization methods.

The successful applicant will be based within the MRC Integrative Epidemiology Unit at the University of Bristol (IEU) located within the Bristol Medical School.

We strongly encourage interested applicants to make informal enquiries to Dr Josine Min (josine.min@bristol.ac.uk) or Dr Lavinia Paternoster (l.paternoster@bristol.ac.uk).

We welcome applications from all members of our community and are particularly encouraging those from diverse groups, such as members of the LGBT+ andBAME communities, to join us.

Read more:

Research Associate/Senior Research Associate in Molecular Epidemiology job with UNIVERSITY OF BRISTOL | 213189 - Times Higher Education (THE)

Drug regulator okays psoriasis injection for limited use in treating COVID-19 patients – Daily Excelsior

NEW DELHI, July 11: Indias drug regulator has approved Itolizumab, used to cure skin ailment psoriasis, for restricted emergency use on COVID-19 patients with moderate to severe acute respiratory distress, officials said.Considering the unmet medical needs to treat COVID-19, Drugs Controller General of India Dr V G Somani approved monoclonal antibody injection Itolizumab for restricted emergency use for the treatment of cytokine release syndrome in moderate to severe acute respiratory distress syndrome patients due to COVID-19, they said on Friday.The approval was given after its clinical trials on COVID-19 patients in India was found satisfactory by the expert committee comprising pulmonologists, pharmacologists and medicine experts from AIIMS, among others, for treatment of cytokine release syndrome, an official told PTI.It is already an approved drug of Biocon for treating psoriasis for last many years, the official said.Written informed consent of each patient is required before the use of this drug, he said. (PTI)

The Leading Daily of Jammu and Kashmir , India

Original post:

Drug regulator okays psoriasis injection for limited use in treating COVID-19 patients - Daily Excelsior

Drug regulator okays psoriasis injection for restricted emergency use in treating COVID-19 patients – The Tribune India

Aditi Tandon

Tribune News Service

New Delhi, July 11

Itolizumab, a monoclonal antibody drug being used in India to treat severe chronic plaque psoriasis a skin condition has now been granted the Restricted Emergency Use authorisation by the Drugs Controller General of India (DCGI) for administration to moderate and severe COVID-19 patients.

Pharma firm Biocon has been manufacturing and marketing this drug for the treatment of patients with moderate to severe chronic plaque psoriasis since 2013 under brand name Alzumab.

This indigenous drug has now been repurposed for COVID-19.

Biocon presented the Phase II clinical trial results generated in the COVID-19 patients to the DCGI. The results of these trials were deliberated in the Subject Expert Committee of the DCGIs office.

The details of the primary endpoint of mortality and other key endpoints of lung function such as improvement in oxygen saturation were presented. Key inflammatory markers were presented to have reduced significantly with the drug thereby preventing hyper-inflammation in COVID-19 patients.

After detailed deliberation and recommendations of the committee, the DCGI has decided to grant permission to market the drug under Restricted Emergency Use of the drug for the treatment of Cytokine Release Syndrome (CRS) in moderate to severe Acute Respiratory Distress Syndrome (ARDS) patients due to COVID-19, subject to some conditions such as informed consent of patients and a risk management plan to be used in the hospital setup only.

The drug will not be available off the shelf.

The average cost of treatment with this indigenous drug is also lesser than comparable drugs which are part of the investigational therapies indicated in the Clinical Management Protocol for COVID-19 of the Ministry of Health and Family Welfare.

More here:

Drug regulator okays psoriasis injection for restricted emergency use in treating COVID-19 patients - The Tribune India

Covid-10 Treatment: Psoriasis injection Itolizumab gets nod for limited use in treating coronavirus patients – Financial Express

Indias drug regulator has approved Itolizumab, used to cure skin ailment psoriasis, for restricted emergency use on COVID-19 patients with moderate to severe acute respiratory distress, officials said.

Considering the unmet medical needs to treat COVID-19, Drugs Controller General of India Dr V G Somani approved monoclonal antibody injection Itolizumab for restricted emergency use for the treatment of cytokine release syndrome in moderate to severe acute respiratory distress syndrome patients due to COVID-19, they said on Friday.

The approval was given after its clinical trials on COVID-19 patients in India was found satisfactory by the expert committee comprising pulmonologists, pharmacologists and medicine experts from AIIMS, among others, for treatment of cytokine release syndrome, an official told PTI.

It is already an approved drug of Biocon for treating psoriasis for last many years, the official said. Written informed consent of each patient is required before the use of this drug, he said.

Here is the original post:

Covid-10 Treatment: Psoriasis injection Itolizumab gets nod for limited use in treating coronavirus patients - Financial Express